


IN THE CLAIMS

12. (Currently Amended) ~~Use~~ A method for treating diseases caused by infectious agents comprising:

administering to a patient in need of treatment an effective amount of at least one bisphosphonic acids of having the general formula



~~in which~~ wherein

A₁, A₂, A₃, A₄, which may be identical or different, are selected from the group ~~which consists~~ consisting of hydrogen, metals of main groups I, II and III of the periodic ~~tables~~ system, such as Na, K, Ca, Mg, Al as well as substituted ammonium compounds, ~~and unsubstituted ammonium compounds~~ and ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group ~~which consists~~ consisting of alkylene with up to 9 carbon atoms, alkenylene with up to 9 carbon atoms, hydroxyalkylene with up to 9 carbon atoms and amidino,

R₁ is selected from the group ~~which consists~~ consisting of H, OH, NH₂, and -CH₃,

R₂ is selected from the group ~~which consists~~ consisting of H, OH, -NH₂, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl,

substituted and unsubstituted heterocyclic residue and ~~the~~ pharmaceutically compatible salts, amides, esters and salts of the esters, wherein when R_2 is a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl, R_2 contains a single substituted or unsubstituted aryl or aralkyl ~~or compounds which, on administration, form the compounds to be administered as metabolites or breakdown products,~~






wherein the at least one bisphosphonic acid inactivates for the production of pharmaceutical preparations for the inactivation of $\gamma\delta$ -T cells for the prevention and treatment of diseases caused by parasites, viruses, bacteria and fungi with the exception of AIDS and AIDS-initiated inflammatory conditions and the sequelae thereof, namely degeneration of connective tissue.

13. (Currently Amended) ~~Use~~ The method according to claim 12, ~~characterized in that wherein A_1 , A_2 , A_3 , A_4 , which may be identical or different, are selected from the group which consists~~ consisting of hydrogen, metals of main groups I, II and III of the periodic system, ~~such as Na, K, Ca, Mg, Al,~~ substituted and unsubstituted ammonium compounds and ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group ~~which consists~~ consisting of alkyl, $(CH_2)_{1-6}$, ~~in particular $(CH_2)_{4-5}$,~~ and amidino,

R_{17} is selected from the group ~~which consists~~ consisting of H, OH, NH_2 , and $-CH_3$,
and

R_2 is selected from the group ~~which consists~~ consisting of $-NH_2$ $-NH_2$,



14. (Currently Amended) The method Use according to claim 13, wherein characterized in that the bisphosphonates at least one bisphosphonic acid ~~are~~ is selected from the group ~~which consists~~ consisting of amino-hydroxymethylidene-bisphosphonic acid, 2-amino-1-hydroxyethylidene-1,1-bisphosphonic acid, 3-amino-1-hydroxypropylidene-1,1-

bisphosphonic acid, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid, amidinomethylene-bisphosphonic acid, 3-methylpentylamino-1-hydroxypropylidene-1,1-bisphosphonic acid, 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonic acid, 1-hydroxy-2-(imidazol-1-yl)-ethylidene-1,1-bisphosphonic acid, cycloheptylaminomethylenediphosphonic acid, 4-chlorophenylthiomethylene-1,1-bisphosphonic acid and the derivatives thereof.

15. (Currently Amended) The method Use according to claim 12, wherein the disease is selected from the group consisting of ~~for the treatment and prophylaxis of~~ acne vulgaris, tuberculosis in humans and animals, leprosy, ~~and further mycobacterioses in humans and~~ animals, paratuberculosis in animals, Campylobacter enteritis infections in humans and animals, ~~of Helicobacter pylori infections, and Chlamydia, for the prevention or treatment of~~ cardiac diseases and vascular diseases, ~~in particular coronary cardiac disease.~~

16. (Currently Amended) The method Use according to claim 12, wherein the at least one bisphosphonic acid eradicates ~~in the eradication of~~ bacteria and viruses.

17. (Currently Amended) The method Use according to claim 16, wherein the at least one bisphosphonic acid eradicates ~~for the eradication of~~ Helicobacter pylori and Chlamydia.


18. (Currently Amended) The method Use according to claim 16, wherein the at least one bisphosphonic acid eradicates ~~for the eradication of eradication of~~ papillomaviruses to prevent ~~tumours~~ tumors, ~~in particular tumours of the reproductive organs caused by papillomaviruses in humans, eradication of~~ eradicates herpesviruses, ~~eradication of human herpesvirus 8 to treat Kaposi's sarcoma, eradication of~~ eradicates cytomegaloviruses before transplantations, ~~eradication of~~ eradicates Epstein-Barr viruses before transplantation and to prevent ~~tumours~~ tumors associated with Epstein-Barr viruses, ~~eradication of~~ eradicates hepatitis viruses to treat chronic liver disease and to prevent liver ~~tumours~~ tumors and cirrhosis of the liver, ~~eradication of~~ eradicates coxsackie-viruses in cardiomyopathy, ~~eradication of~~ eradicates coxsackie-viruses in diabetes mellitus patients, ~~eradication of~~ eradicates immunodeficiency viruses in humans and animals, ~~treatment of~~ treats accompanying infections in AIDS patients, ~~treatment of~~ treats viral respiratory tract inflammation ~~of viral causation (laryngeal papilloma, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumonia),~~ treats viral infections of the liver and gall system ~~(hepatitis, cholangitis, hepatocellular carcinoma),~~ treats viral infections of the lymphatic tissue ~~(mononucleosis, lymphadenitis),~~ treats viral infections of the haemopoietic system, treats viral infections of the skin ~~(warts, dermatitis, herpes labialis, herpes febrilis, herpes zoster, shingles),~~ treats viral infections of the mucous membranes ~~(papillomas, conjunctival papillomas, hyperplasia, dysplasia),~~ treats viral infections of the cardiovascular system ~~(arteriitis, myocarditis, endocarditis, pericarditis),~~ treats viral infections of the kidney and urinary system, treats viral infections of the reproductive organs ~~(anogenital lesions, warts, genital warts, sharp condylomas, dysplasia, papillomas, cervical dysplasia, condyloma acuminatum, epidermodysplasia verruciformis),~~ of the locomotory organs ~~(myositis, myalgia), with the exception of AIDS~~

~~and AIDS initiated inflammatory conditions and the sequelae thereof, namely degeneration of connective tissue.~~

19. (Currently Amended) The method Use according to claim 18, wherein the at least one bisphosphonic acid eradicates for the eradication of the hepatitis C virus.

20. (Currently Amended) A composition for the treatment of diseases caused by infectious agents comprising:

at least one bisphosphonic acid having the general formula



wherein

A₁, A₂, A₃, A₄, which may be identical or different, are selected from the group consisting of hydrogen, metals of main groups I, II and III of the periodic table, substituted ammonium compounds, unsubstituted ammonium compounds and ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group consisting of alkylene with up to 9 carbon atoms, alkenylene with up to 9 carbon atoms, hydroxyalkylene with up to 9 carbon atoms and amidino,

R₁ is selected from the group consisting of H, OH, NH₂ and -CH₃,

R₂ is selected from the group consisting of H, OH, -NH₂, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue and pharmaceutically compatible salts, amides, esters and salts of the esters, wherein when R₂ is a substituted or unsubstituted aryl or a substituted or unsubstituted aralkyl, R₂ contains a single substituted or unsubstituted aryl or aralkyl, and

a pharmaceutically acceptable excipient,

wherein the at least one bisphosphonic acid inactivates $\gamma\delta$ -T cells~~Use according to claim 12 in a pharmaceutical preparation which additionally contains a pharmaceutically acceptable excipient.~~

21. (Currently Amended) ~~Use according to claim 12~~ The composition according to claim 20, wherein the composition is as an adjuvant to vaccines.

Please add the following new claims:

--22. (New) The method according to claim 12, wherein the metals of main groups I, II and III of the periodic table are selected from the group consisting of Na, K, Ca, Mg and Al.

23. (New) The method according to claim 18, wherein the at least one bisphosphonic acid treats laryngeal papilloma, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumoniahepatitis, cholangitis, hepatocellular carcinoma, mononucleosis, lymphadenitis, warts, dermatitis, herpes labialis, herpes febrilis, herpes zoster, shingles,

conjunctival papillomas, hyperplasia, dysplasia, arteriitis, myocarditis, endocarditis, pericarditis, anogenital lesions, warts, genital warts, sharp condylomas, dysplasia, papillomas, cervical dysplasia, condyloma acuminatum, epidermodysplasia verruciformis, myositis and myalgia.

24. (New) The method according to claim 12, wherein the infectious agents are selected from the group consisting of viruses, bacteria, parasites and fungi.

25. (New) The composition according to claim 20, wherein the infectious agents are selected from the group consisting of viruses, bacteria, parasites and fungi.--